ALDX

Aldeyra Therapeutics, Inc.

4.62

USD

ALDX Earnings Reports

Positive Surprise Ratio

ALDX beat 25 of 40 last estimates.

63%

Next Report

Date of Next Report

Feb 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

$24.73M

-$0.17

Implied change from Q3 25 (Revenue/ EPS)

+30.77%

Implied change from Q4 24 (Revenue/ EPS)

-37.04%

Aldeyra Therapeutics, Inc. earnings per share and revenue

On Nov 05, 2025, ALDX reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.24 USD, resulting in a 47.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.43% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 24.73 million USD, implying an increase of 30.77% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Aldeyra Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Aldeyra Therapeutics, Inc. reported EPS of -$0.13, beating estimates by 47.98%, and revenue of $0.00, 0% as expectations.

How did the market react to Aldeyra Therapeutics, Inc.'s Q3 2025 earnings?

The stock price moved down -2.43%, changed from $4.93 before the earnings release to $4.81 the day after.

When is Aldeyra Therapeutics, Inc. expected to report next?

The next earning report is scheduled for Feb 26, 2026.

What are the forecasts for Aldeyra Therapeutics, Inc.'s next earnings report?

Based on 8 analysts, Aldeyra Therapeutics, Inc. is expected to report EPS of -$0.17 and revenue of $24.73M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.